Compare GDTC & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDTC | NTIP |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 32.0M |
| IPO Year | 2023 | 1998 |
| Metric | GDTC | NTIP |
|---|---|---|
| Price | $1.66 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 78.6K | 8.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | ★ 6.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $573,193.00 | $150,000.00 |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.03 | N/A |
| 52 Week Low | $1.50 | $1.16 |
| 52 Week High | $4.05 | $1.90 |
| Indicator | GDTC | NTIP |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 42.71 |
| Support Level | $1.71 | $1.37 |
| Resistance Level | $2.12 | $1.46 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.81 | 26.09 |
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.